+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-01-14Number of Pages: 90

Albumin Market (Types: Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin; Applications: Drug Formulation and Drug Delivery, Vaccines, and Component of Media) - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast 2014 - 2020


The optimal formulation of active pharmaceutical ingredients (API) into efficacious dosage form to ensure stability and acceptable shelf life is a critical and prime prerequisite. The use of albumin as an excipient with proven preference in culture media, stabilizer in pharmaceutical and biotechnology products, vaccines, and as a drug carrier in the form of nanoparticles or microspheres has made it a multifunctional excipient in the formulation development. The unique features of albumin such as amphiphilicity and surface-active properties, as well as high glass transition temperature make it a suitable excipient. The global albumin market was valued at USD 704.9 million in 2013 and is expected to reach USD 828.2 million by 2020, growing at a CAGR of 2.3% during the forecast period 2014 to 2020. Improved product stability, enhancement in protein purification technology and emerging use of recombinant albumin are some factors propelling market growth.

The global albumin market is broadly categorized into type, applications and geography. Human serum albumin, bovine serum albumin and recombinant albumin altogether comprise the albumin type segment. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. Rising ethical concerns regarding cruelty toward bovine fetuses in deriving bovine serum as well as the retention of some amount of impurities in the albumin excipient has prompted researchers and manufacturers to opt for alternatives. Moreover, trend towards use of serum-free and chemically defined media could hamper the use of albumin as an excipient. Recombinant albumin is anticipated to be the fastest growing segment at a CAGR of 2.7% during the forecast period. Applications for this market include drug formulation and drug delivery, vaccines, and component of media. The drug formulation segment is expected to grow at the fastest CAGR of 2.4% during the forecast period from 2014 to 2020. Some examples of products with albumin as an excipient include Kogenate (Bayer), Avonex (Biogen Idec), Intron A (Merck) and Aralast (Baxter).

Geographically, the global albumin market has been segmented into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The albumin market is majorly concentrated in the U.S., followed by Europe and Asia, especially China. The dominance of North America is attributed to the presence of a large number of pharmaceutical companies and research institutions where albumin consumption is higher. Technological development in drug formulation and drug delivery and increased access to technologies such as use of albumin in culture media would serve as an opportunity for investors in emerging countries. Manufacturers investing in these developing markets and increase in contract research manufacturing are expected to boost market growth due to the increasing demand and awareness among end-users about albumin as an excipient.

CSL Behring, HiMedia Laboratories Pvt. Ltd., InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific and MedxBio Pte. Ltd. are some of the major companies operating in the global albumin market.

albumin-market


Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
     1.3.1 Sources
             1.3.1.1 Secondary Research
             1.3.1.2 Primary Research
     1.3.2 Assumptions and Limitations
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Albumin Market (2013 & 2020)
2.2 Comparative Analysis: Global Albumin Market Revenue, by Geography, 2013 & 2020 (Value %)
2.3 Global Albumin Market Volume, by Geography, 2012 - 2020 (Kilograms)

Chapter 3 Albumin Market Overview
3.1 Introduction
3.2 Market Dynamics
     3.2.1 Drivers
             3.2.1.1 Improved product stability with albumin as an excipient leading to increase in its demand
             3.2.1.2 Improvements in protein purification and molecular separation technology to boost market growth
             3.2.1.3 Use of recombinant albumin to drive the albumin market
     3.2.2 Restraints
             3.2.2.1 Stringent regulations, cost and health care issues are anticipated to affect the market
             3.2.2.2 Trend toward serum-free, specialty and customized media solutions could hamper the albumin market
     3.2.3 Opportunities
             3.2.3.1 Expanding applications of albumin such as nanotechnology would revolutionize the albumin market, particularly recombinant albumin
             3.2.3.2 Focus on emerging regions to provide immense potential for the global albumin market
3.3 Porter’s Five Force Analysis for the Global Albumin Market
     3.3.1 Bargaining Power of Suppliers
     3.3.2 Bargaining Power of Buyers
     3.3.3 Threat of Substitutes
     3.3.4 Threat of New Entrants
     3.3.5 Competitive Rivalry
3.4 Market Attractiveness Analysis: Global Albumin Market, by Geography
3.5 Event Impact Analysis
3.6 Clinical Pipeline Analysis
3.7 Examples of Products Containing Albumin as an Excipient

Chapter 4 Global Albumin Market Revenue (USD Million), by Type, 2012 – 2020
4.1 Introduction
     4.1.1 Global Albumin Market Revenue, by Type, 2012 - 2020 (USD Million)
     4.1.2 Comparative Analysis: Global Albumin Market Revenue, by Type, 2013 & 2020 (Value %)
     4.1.3 Price Range for Each Albumin Type
4.2 Human Serum Albumin (HSA)
     4.2.1 Global HSA Market Revenue, 2012 – 2020 (USD Million)
4.3 Bovine Serum Albumin (BSA)
     4.3.1 Global BSA Market Revenue, 2012 – 2020 (USD Million)
4.4 Recombinant Albumin (rAlbumin)
     4.4.1 Global rAlbumin Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 Global Albumin Market Revenue (USD Million) and Volume (kg), by Application, 2012 - 2020
5.1 Introduction
     5.1.1 Global Albumin Market Revenue, by Application, 2012 - 2020 (USD Million)
     5.1.2 Comparative Analysis: Global Albumin Market Revenue, by Application, 2013 & 2020 (Value %)
5.2 Drug Formulation and Drug Delivery
     5.2.1 Global Drug Formulation and Drug Delivery Market Revenue, 2012 – 2020 (USD Million)
     5.2.2 Global Drug Formulation and Drug Delivery Market Volume, 2012 – 2020 (kilograms)
     5.2.3 Examples of Albumin-based Drug Conjugates for Different Therapeutic Applications
5.3 Vaccines
     5.3.1 Global Vaccines Market Revenue, 2012 – 2020 (USD Million)
     5.3.2 Global Vaccines Market Volume, 2012 – 2020 (kilograms)
5.4 Component of Media
     5.4.1 Global Component of Media Market Revenue, 2012 – 2020 (USD Million)
     5.4.2 Global Component of Media Market Volume, 2012 – 2020 (kilograms)
     5.4.3 Role of Albumin in Cryopreservation
     5.4.4 Albumin Use in Cell Culture Media

Chapter 6 Global Albumin Market Revenue (USD Million) & Volume (kg), by Geography, 2012 - 2020
6.1 Overview
     6.1.1 Global Albumin Market Revenue, by Geography, 2012 - 2020 (USD Million)
     6.1.2 Global Albumin Market Volume, by Geography, 2012 - 2020 (kilograms)
6.2 North America
     6.2.1 North America Albumin Market Revenue, 2012 – 2020, (USD Million)
     6.2.2 North America Albumin Market Volume, 2012 – 2020, (kilograms)
6.3 Europe
     6.3.1 Europe Albumin Market Revenue, 2012 – 2020 (USD Million)
     6.3.2 Europe Albumin Market Volume, 2012 – 2020 (kilograms)
6.4 Asia Pacific
     6.4.1 Asia Pacific Albumin Market Revenue, 2012 – 2020 (USD Million)
     6.4.2 Asia Pacific Albumin Market Volume, 2012 – 2020 (kilograms)
6.5 Rest of the World (RoW)
     6.5.1 Rest of the World Albumin Market Revenue, 2012 – 2020 (USD Million)
     6.5.2 Rest of the World Albumin Market Volume, 2012 – 2020 (kilograms)

Chapter 7 Recommendations
7.1 Marketing Strategies for Success
     7.1.1 Investment in research and development and collaborations
     7.1.2 Exploring nanotechnology applications of albumin as an excipient
     7.1.3 Expansion of distribution network to strengthen position in emerging markets
7.2 Barriers to be Considered
     7.2.1 Insufficient quantity of plasma and risk of disease transmission through the use of albumin as an excipient
     7.2.2 Significant cost of investment

Chapter 8 Company Profiles
8.1 CSL Behring LLC
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategies
     8.1.5 Recent Developments
8.2 HiMedia Laboratories
     8.2.1 Company Overview
     8.2.2 Financial Overview
     8.2.3 Product Portfolio
     8.2.4 Business Strategies
     8.2.5 Recent Developments
8.3 InVitria (Ventria Bioscience)
     8.3.1 Company Overview
     8.3.2 Financial Overview
     8.3.3 Product Portfolio
     8.3.4 Business Strategies
     8.3.5 Recent Developments
8.4 MedxBio Pte. Ltd.
     8.4.1 Company Overview
     8.4.2 Financial Overview
     8.4.3 Product Portfolio
     8.4.4 Business Strategies
8.5 Mitsubishi Tanabe Pharma
     8.5.1 Company Overview
     8.5.2 Financial Overview
     8.5.3 Product Portfolio
     8.5.4 Business Strategies
     8.5.5 Recent Developments
8.6 Novozymes A/S
     8.6.1 Company Overview
     8.6.2 Financial Overview
     8.6.3 Product Portfolio
     8.6.4 Business Strategies
     8.6.5 Recent Developments
8.7 Octapharma AG
     8.7.1 Company Overview
     8.7.2 Financial Overview
     8.7.3 Product Portfolio
     8.7.4 Business Strategies
     8.7.5 Recent Developments
8.8 RayBiotech, Inc.
     8.8.1 Company Overview:
     8.8.2 Financial Overview
     8.8.3 Product Portfolio
     8.8.4 Business Strategies
     8.8.5 Recent Developments
8.9 Sigma-Aldrich Corporation
     8.9.1 Company Overview
     8.9.2 Financial Overview
     8.9.3 Product Portfolio
     8.9.4 Business Strategies
     8.9.5 Recent Developments
8.10 Thermo Fisher Scientific
     8.10.1 Company Overview
     8.10.2 Financial Overview
     8.10.3 Product Portfolio
     8.10.4 Business Strategies
     8.10.5 Recent Developments

List of Figures

FIG. 1 Market Segmentation: Global Albumin Market
FIG. 2 Comparative Analysis: Global Albumin Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 3 Global Albumin Market Volume, by Geography, 2012 - 2020 (Kilograms)
FIG. 4 Porter’s Five Forces Analysis: Global Albumin Market
FIG. 5 Market Attractiveness Analysis: Global Albumin Market, by Geography
FIG. 6 Comparative Analysis: Global Albumin Market Revenue, by Type, 2013 & 2020 (Value %)
FIG. 7 Global HSA Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global BSA Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 Global rAlbumin Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Comparative Analysis: Global Albumin Market Revenue, by Application, 2013 & 2020 (Value %)
FIG. 11 Global Drug Formulation and Drug Delivery Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 Global Drug Formulation and Drug Delivery Market Volume, 2012 – 2020 (kilograms)
FIG. 13 Global Vaccines Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Vaccines Market Volume, 2012 – 2020 (kilograms)
FIG. 15 Global Component of Media Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Component of Media Market Volume, 2012 – 2020 (kilograms)
FIG. 17 North America Albumin Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 North America Albumin Market Volume, 2012 – 2020 (kilograms)
FIG. 19 Europe Albumin Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Europe Albumin Market Volume, 2012 – 2020 (kilograms)
FIG. 21 Asia Pacific Albumin Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Asia Pacific Albumin Market Volume, 2012 – 2020 (kilograms)
FIG. 23 Rest of the World Albumin Market Revenue, 2012 – 2020 (USD Million)
FIG. 24 Rest of the World Albumin Market Volume, 2012 – 2020 (kilograms)
FIG. 25 CSL Behring, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 26 Mitsubishi Tanabe Pharma: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 27 Novozymes: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 28 Octapharma AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Sigma-Aldrich Corporation: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 30 Thermo Fisher Scientific: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Albumin Market (2013 & 2020)
TABLE 3 Event Impact Analysis: Global Albumin Market
TABLE 4 Ongoing Clinical Trials with Albumin as an Excipient
TABLE 5 Examples of Products Containing Albumin as an Excipient
TABLE 6 Global Albumin Market Revenue, by Type, 2012 - 2020 (USD Million)
TABLE 7 Price Range for Each Albumin Type (USD/ kg)
TABLE 8 Global Albumin Market Revenue, by Application, 2012 - 2020 (USD Million)
TABLE 9 Examples of Albumin-based Drug Conjugates for Different Therapeutic Applications
TABLE 10 Global Albumin Market Revenue, by Geography, 2012 - 2020 (USD Million)
TABLE 11 Global Albumin Market Volume, by Geography, 2012 - 2020 (kilograms)

Appropriate selection of excipients during the new product development is one of the critical in the pharmaceutical formulations. Criteria for selection of suitable excipient depend on the physical, chemical and biological properties of the excipient. Primarily, it should help stabilize and protect the drug/active pharmaceutical ingredient (API) in the formulation against degradation, oxidation or aggregation, during manufacturing, transport and storage. Preformulation studies comprise investigation of drug-excipient interactions that help in selection of appropriate excipients to achieve the desired properties for the final drug product. Albumin is a well characterized protein and functions as a therapeutic, diagnostic agent, as well as an excipient. As an excipient, albumin has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media in vaccine production. Stable nature of albumin makes its handling and storage easier than other proteins, making it suitable for use as an excipient. Albumin due to its intrinsic stability can be heated at 60°C for 10 hours facilitating virus inactivation during manufacturing.

This report studies the global market for albumin encompassing type, applications and geography. Types of albumin include human serum albumin, bovine serum albumin and recombinant albumin. Major applications for albumin as an excipient comprise drug formulation and drug delivery, vaccines and component of medium. Each of these segments has been analyzed in detail from market trends and recent developments to future outlook and opportunities. The report provides the albumin market size in terms of value (USD million) and volume (kg) for each segment and sub-segment for the period from 2012 to 2020, considering the macro- and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall albumin market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 as historical year and 2013 as the base year. The global albumin market report also includes an elaborate executive summary, which covers a market snapshot representing key findings from the study.

Geographically, the global albumin market has been segmented into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast in terms of value (USD million) and volume (kg) for each of these regions along with the CAGR for the forecast period from 2014 to 2020 have been provided in the report. A detailed qualitative analysis of the major factors determining market dynamics such as drivers, restraints and opportunities, along with the market attractiveness analysis are discussed in the market overview section of the report. The study also provides a list of recommendations for new companies willing to enter the market and for existing companies to increase market shares, which is likely to help in the decision-making process. Event impact analysis and clinical pipeline analysis have also been provided for albumin as an excipient in this report that will help in understanding the major events impacting the albumin market growth. Number of clinical trials also demonstrates the potential of albumin use as an excipient in pharmaceutical formulations.

The study is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interaction via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases for patents, clinical trials, demographics, disease incidence/prevalence, etc. The key players operating in the albumin market are CSL Behring LLC, HiMedia Laboratories Pvt. Ltd., InVitria, MedzBio Pte. Ltd., Mitsubishi Tanabe Pharma Corporation, Novozymes A/S, Octapharma AG, RayBiotech, Inc., Sigma-Aldrich Corporation, and Thermo Fisher Scientific.  

The global albumin market is segmented as follows:
  • Albumin Market Revenue (USD Million), by Type
    • Human Serum Albumin
    • Bovine Serum Albumin
    • Recombinant Albumin
  • Albumin Market Revenue (USD Million) and Volume (kg), by Application
    • Drug Formulation and Drug Delivery
    • Vaccines
    • Component of Medium
  • Albumin Market Revenue (USD Million) and Volume (kg), by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World